-
Je něco špatně v tomto záznamu ?
Efficient Delivery of Hydrophilic Small Molecules to Retinal Cell Lines Using Gel Core-Containing Solid Lipid Nanoparticles
L. Huang, E. Himawan, S. Belhadj, RO. Pérez García, F. Paquet Durand, N. Schipper, M. Buzgo, A. Simaite, V. Marigo
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
H2020-MSCA-ITN-765441
European Union
Charlotte and Tistou Kerstan Foundation
Charlotte and Tistou Kerstan Foundation
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
- Publikační typ
- časopisecké články MeSH
In this study, we developed a novel solid lipid nanoparticle (SLN) formulation for drug delivery of small hydrophilic cargos to the retina. The new formulation, based on a gel core and composite shell, allowed up to two-fold increase in the encapsulation efficiency. The type of hydrophobic polyester used in the composite shell mixture affected the particle surface charge, colloidal stability, and cell internalization profile. We validated SLNs as a drug delivery system by performing the encapsulation of a hydrophilic neuroprotective cyclic guanosine monophosphate analog, previously demonstrated to hold retinoprotective properties, and the best formulation resulted in particles with a size of ±250 nm, anionic charge > -20 mV, and an encapsulation efficiency of ±60%, criteria that are suitable for retinal delivery. In vitro studies using the ARPE-19 and 661W retinal cell lines revealed the relatively low toxicity of SLNs, even when a high particle concentration was used. More importantly, SLN could be taken up by the cells and the release of the hydrophilic cargo in the cytoplasm was visually demonstrated. These findings suggest that the newly developed SLN with a gel core and composite polymer/lipid shell holds all the characteristics suitable for the drug delivery of small hydrophilic active molecules into retinal cells.
Center for Neuroscience and Neurotechnology Via Campi 287 41125 Modena Italy
Department of Life Sciences University of Modena and Reggio Emilia 41125 Modena Italy
Research and Development Department InoCure s r o 11000 Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010371
- 003
- CZ-PrNML
- 005
- 20220425131817.0
- 007
- ta
- 008
- 220420s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics14010074 $2 doi
- 035 __
- $a (PubMed)35056970
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Huang, Li $u Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
- 245 10
- $a Efficient Delivery of Hydrophilic Small Molecules to Retinal Cell Lines Using Gel Core-Containing Solid Lipid Nanoparticles / $c L. Huang, E. Himawan, S. Belhadj, RO. Pérez García, F. Paquet Durand, N. Schipper, M. Buzgo, A. Simaite, V. Marigo
- 520 9_
- $a In this study, we developed a novel solid lipid nanoparticle (SLN) formulation for drug delivery of small hydrophilic cargos to the retina. The new formulation, based on a gel core and composite shell, allowed up to two-fold increase in the encapsulation efficiency. The type of hydrophobic polyester used in the composite shell mixture affected the particle surface charge, colloidal stability, and cell internalization profile. We validated SLNs as a drug delivery system by performing the encapsulation of a hydrophilic neuroprotective cyclic guanosine monophosphate analog, previously demonstrated to hold retinoprotective properties, and the best formulation resulted in particles with a size of ±250 nm, anionic charge > -20 mV, and an encapsulation efficiency of ±60%, criteria that are suitable for retinal delivery. In vitro studies using the ARPE-19 and 661W retinal cell lines revealed the relatively low toxicity of SLNs, even when a high particle concentration was used. More importantly, SLN could be taken up by the cells and the release of the hydrophilic cargo in the cytoplasm was visually demonstrated. These findings suggest that the newly developed SLN with a gel core and composite polymer/lipid shell holds all the characteristics suitable for the drug delivery of small hydrophilic active molecules into retinal cells.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Himawan, Erico $u Research and Development Department, InoCure s.r.o, 11000 Prague, Czech Republic $1 https://orcid.org/000000021610458X
- 700 1_
- $a Belhadj, Soumaya $u Cell Death Mechanism Group, Institute for Ophthalmic Research, University of Tuebingen, 72076 Tuebingen, Germany
- 700 1_
- $a Pérez García, Raúl Oswaldo $u Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, RISE Research Institutes of Sweden, Forskargatan 18, 151 36 Södertälje, Sweden
- 700 1_
- $a Paquet Durand, François $u Cell Death Mechanism Group, Institute for Ophthalmic Research, University of Tuebingen, 72076 Tuebingen, Germany $1 https://orcid.org/0000000173555742
- 700 1_
- $a Schipper, Nicolaas $u Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, RISE Research Institutes of Sweden, Forskargatan 18, 151 36 Södertälje, Sweden
- 700 1_
- $a Buzgo, Matej $u Research and Development Department, InoCure s.r.o, 11000 Prague, Czech Republic
- 700 1_
- $a Simaite, Aiva $u Research and Development Department, InoCure s.r.o, 11000 Prague, Czech Republic $1 https://orcid.org/0000000342966842
- 700 1_
- $a Marigo, Valeria $u Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy $u Center for Neuroscience and Neurotechnology, Via Campi 287, 41125 Modena, Italy
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 1 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35056970 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220420 $b ABA008
- 991 __
- $a 20220425131814 $b ABA008
- 999 __
- $a ind $b bmc $g 1784571 $s 1161569
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 14 $c 1 $e 20211228 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a H2020-MSCA-ITN-765441 $p European Union
- GRA __
- $a Charlotte and Tistou Kerstan Foundation $p Charlotte and Tistou Kerstan Foundation
- LZP __
- $a Pubmed-20220420